These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effects of N1,N3-diallyluracil and N1,N3-diallylthymine on hepatic drug-metabolizing enzymes of mice.
    Author: Tateoka Y, Kimura T, Watanabe K, Yamamoto I, Ho IK.
    Journal: Res Commun Chem Pathol Pharmacol; 1989 Apr; 64(1):135-43. PubMed ID: 2748995.
    Abstract:
    Potentiation mechanism of pentobarbital (PB)-induced sleep by N1,N3-diallyluracil (DAU) and N1,N3-diallylthymine (DAT) was studied in mice. In mice receiving DAU (40 mg/kg, i.p.) 180 min earlier, PB (40 mg/kg, i.p.)-induced sleeping time was significantly enhanced. At this time point, DAU administration also significantly decreased the enzyme activity of ethylmorphine (EM) N-demethylase and the content of cytochrome P-450 in the mouse hepatic microsomes. On the other hand, DAT (40 mg/kg, i.p.) showed significance prolonging effect until 60 min after administration. DAT significantly decreased the content of cytochrome P-450 at 10, 60 and 180 min. DAU exhibited non-competitive inhibition on the EM N-demethylase activity in vitro and DAT showed inhibition of mixed type. However, only DAU (200 micrograms/mouse) significantly prolonged the PB (40 mg/kg, i.p.)-induced sleeping time by intracerebroventricular (i.c.v.) routes of administration. These results suggest that DAU prolonged PB-induced sleep by both the CNS depressant effect and the inhibition of the PB metabolism, whereas DAT enhanced sleep is partly responsible only or its inhibition of PB metabolism.
    [Abstract] [Full Text] [Related] [New Search]